Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination

Thomas V. Adamkiewicz, Sharada Sarnaik, George R. Buchanan, Rathi V. Iyer, Scott T. Miller, Charles H. Pegelow, Zora R. Rogers, Elliott Vichinsky, John Elliott, Richard R. Facklam, Katherine L. O'Brien, Benjamin Schwartz, Chris A. Van Beneden, Michael J. Cannon, James R. Eckman, Harry Keyserling, Kevin Sullivan, Wing Yen Wong, Winfred C. Wang

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Rates and severity of pneumococcal infections in children with sickle cell disease were examined before licensure of pneumococcal-conjugated vaccine (PVC). Rates of peak invasive infection rates in 1-year-old children with hemoglobin SS and mortality in those 0 to 10 years of age were 36.5 to 63.4 and 1.4 to 2.8 per 1000 person-years, respectively (>10 and 100 times as frequent as in the general population). Overall, 71% of serotyped isolates (n = 80) were PVC serotypes and 71% of nonvaccine serotype strains were penicillin-sensitive. Clinical presentation in children with hemoglobin SS (n = 71; more with hypotension) and hemoglobin SC (n = 18; more with acute chest syndrome, otitis media) differed. Penicillin nonsusceptibility (38% of isolates) varied between geographic study sites. Penicillin prophylaxis appeared less effective against intermediate and resistant strains. Of all infected children, meningitis developed in 20% and 15% died (hemoglobin SS, n = 15 and 11; hemoglobin SC, n = 1 each). Factors associated with death included age >4 years (58%), serotype 19F, and not being followed by a hematologist (42% each). The pneumococcal-polysaccharide vaccine was 80.4% effective within 3 years after vaccination (95% CI, 39.7, 93.6). Children with sickle cell disease of all ages may benefit from PVC boosted with polysaccharide vaccination.

Original languageEnglish (US)
Pages (from-to)438-444
Number of pages7
JournalJournal of Pediatrics
Volume143
Issue number4
DOIs
StatePublished - Oct 2003

Fingerprint

Pneumococcal Infections
Sickle Cell Anemia
Microbial Drug Resistance
Pneumococcal Vaccines
Penicillins
Polysaccharides
Vaccination
Sickle Hemoglobin
Hemoglobins
Acute Chest Syndrome
Otitis Media
Licensure
Meningitis
Hypotension
Mortality
Infection
Population
Serogroup

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. / Adamkiewicz, Thomas V.; Sarnaik, Sharada; Buchanan, George R.; Iyer, Rathi V.; Miller, Scott T.; Pegelow, Charles H.; Rogers, Zora R.; Vichinsky, Elliott; Elliott, John; Facklam, Richard R.; O'Brien, Katherine L.; Schwartz, Benjamin; Van Beneden, Chris A.; Cannon, Michael J.; Eckman, James R.; Keyserling, Harry; Sullivan, Kevin; Wong, Wing Yen; Wang, Winfred C.

In: Journal of Pediatrics, Vol. 143, No. 4, 10.2003, p. 438-444.

Research output: Contribution to journalArticle

Adamkiewicz, TV, Sarnaik, S, Buchanan, GR, Iyer, RV, Miller, ST, Pegelow, CH, Rogers, ZR, Vichinsky, E, Elliott, J, Facklam, RR, O'Brien, KL, Schwartz, B, Van Beneden, CA, Cannon, MJ, Eckman, JR, Keyserling, H, Sullivan, K, Wong, WY & Wang, WC 2003, 'Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination', Journal of Pediatrics, vol. 143, no. 4, pp. 438-444. https://doi.org/10.1067/S0022-3476(03)00331-7
Adamkiewicz, Thomas V. ; Sarnaik, Sharada ; Buchanan, George R. ; Iyer, Rathi V. ; Miller, Scott T. ; Pegelow, Charles H. ; Rogers, Zora R. ; Vichinsky, Elliott ; Elliott, John ; Facklam, Richard R. ; O'Brien, Katherine L. ; Schwartz, Benjamin ; Van Beneden, Chris A. ; Cannon, Michael J. ; Eckman, James R. ; Keyserling, Harry ; Sullivan, Kevin ; Wong, Wing Yen ; Wang, Winfred C. / Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. In: Journal of Pediatrics. 2003 ; Vol. 143, No. 4. pp. 438-444.
@article{e0abdcc05ac44aefa2c57ce41c02ab50,
title = "Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination",
abstract = "Rates and severity of pneumococcal infections in children with sickle cell disease were examined before licensure of pneumococcal-conjugated vaccine (PVC). Rates of peak invasive infection rates in 1-year-old children with hemoglobin SS and mortality in those 0 to 10 years of age were 36.5 to 63.4 and 1.4 to 2.8 per 1000 person-years, respectively (>10 and 100 times as frequent as in the general population). Overall, 71{\%} of serotyped isolates (n = 80) were PVC serotypes and 71{\%} of nonvaccine serotype strains were penicillin-sensitive. Clinical presentation in children with hemoglobin SS (n = 71; more with hypotension) and hemoglobin SC (n = 18; more with acute chest syndrome, otitis media) differed. Penicillin nonsusceptibility (38{\%} of isolates) varied between geographic study sites. Penicillin prophylaxis appeared less effective against intermediate and resistant strains. Of all infected children, meningitis developed in 20{\%} and 15{\%} died (hemoglobin SS, n = 15 and 11; hemoglobin SC, n = 1 each). Factors associated with death included age >4 years (58{\%}), serotype 19F, and not being followed by a hematologist (42{\%} each). The pneumococcal-polysaccharide vaccine was 80.4{\%} effective within 3 years after vaccination (95{\%} CI, 39.7, 93.6). Children with sickle cell disease of all ages may benefit from PVC boosted with polysaccharide vaccination.",
author = "Adamkiewicz, {Thomas V.} and Sharada Sarnaik and Buchanan, {George R.} and Iyer, {Rathi V.} and Miller, {Scott T.} and Pegelow, {Charles H.} and Rogers, {Zora R.} and Elliott Vichinsky and John Elliott and Facklam, {Richard R.} and O'Brien, {Katherine L.} and Benjamin Schwartz and {Van Beneden}, {Chris A.} and Cannon, {Michael J.} and Eckman, {James R.} and Harry Keyserling and Kevin Sullivan and Wong, {Wing Yen} and Wang, {Winfred C.}",
year = "2003",
month = "10",
doi = "10.1067/S0022-3476(03)00331-7",
language = "English (US)",
volume = "143",
pages = "438--444",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination

AU - Adamkiewicz, Thomas V.

AU - Sarnaik, Sharada

AU - Buchanan, George R.

AU - Iyer, Rathi V.

AU - Miller, Scott T.

AU - Pegelow, Charles H.

AU - Rogers, Zora R.

AU - Vichinsky, Elliott

AU - Elliott, John

AU - Facklam, Richard R.

AU - O'Brien, Katherine L.

AU - Schwartz, Benjamin

AU - Van Beneden, Chris A.

AU - Cannon, Michael J.

AU - Eckman, James R.

AU - Keyserling, Harry

AU - Sullivan, Kevin

AU - Wong, Wing Yen

AU - Wang, Winfred C.

PY - 2003/10

Y1 - 2003/10

N2 - Rates and severity of pneumococcal infections in children with sickle cell disease were examined before licensure of pneumococcal-conjugated vaccine (PVC). Rates of peak invasive infection rates in 1-year-old children with hemoglobin SS and mortality in those 0 to 10 years of age were 36.5 to 63.4 and 1.4 to 2.8 per 1000 person-years, respectively (>10 and 100 times as frequent as in the general population). Overall, 71% of serotyped isolates (n = 80) were PVC serotypes and 71% of nonvaccine serotype strains were penicillin-sensitive. Clinical presentation in children with hemoglobin SS (n = 71; more with hypotension) and hemoglobin SC (n = 18; more with acute chest syndrome, otitis media) differed. Penicillin nonsusceptibility (38% of isolates) varied between geographic study sites. Penicillin prophylaxis appeared less effective against intermediate and resistant strains. Of all infected children, meningitis developed in 20% and 15% died (hemoglobin SS, n = 15 and 11; hemoglobin SC, n = 1 each). Factors associated with death included age >4 years (58%), serotype 19F, and not being followed by a hematologist (42% each). The pneumococcal-polysaccharide vaccine was 80.4% effective within 3 years after vaccination (95% CI, 39.7, 93.6). Children with sickle cell disease of all ages may benefit from PVC boosted with polysaccharide vaccination.

AB - Rates and severity of pneumococcal infections in children with sickle cell disease were examined before licensure of pneumococcal-conjugated vaccine (PVC). Rates of peak invasive infection rates in 1-year-old children with hemoglobin SS and mortality in those 0 to 10 years of age were 36.5 to 63.4 and 1.4 to 2.8 per 1000 person-years, respectively (>10 and 100 times as frequent as in the general population). Overall, 71% of serotyped isolates (n = 80) were PVC serotypes and 71% of nonvaccine serotype strains were penicillin-sensitive. Clinical presentation in children with hemoglobin SS (n = 71; more with hypotension) and hemoglobin SC (n = 18; more with acute chest syndrome, otitis media) differed. Penicillin nonsusceptibility (38% of isolates) varied between geographic study sites. Penicillin prophylaxis appeared less effective against intermediate and resistant strains. Of all infected children, meningitis developed in 20% and 15% died (hemoglobin SS, n = 15 and 11; hemoglobin SC, n = 1 each). Factors associated with death included age >4 years (58%), serotype 19F, and not being followed by a hematologist (42% each). The pneumococcal-polysaccharide vaccine was 80.4% effective within 3 years after vaccination (95% CI, 39.7, 93.6). Children with sickle cell disease of all ages may benefit from PVC boosted with polysaccharide vaccination.

UR - http://www.scopus.com/inward/record.url?scp=0242298737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242298737&partnerID=8YFLogxK

U2 - 10.1067/S0022-3476(03)00331-7

DO - 10.1067/S0022-3476(03)00331-7

M3 - Article

C2 - 14571216

AN - SCOPUS:0242298737

VL - 143

SP - 438

EP - 444

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 4

ER -